Tokyo, Aug. 8 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000058730) titled 'A study to examine the safety and tolerability of a home-based exercise program after local therapy for liver cancer' on Aug. 8.

Study Type: Interventional

Study Design: Basic Design - Single arm Randomization - Non-randomized Blinding - Open -no one is blinded Control - Uncontrolled

Primary Sponsor: Institute - Keio University

Condition: Condition - Patients with liver cancer who underwent local therapy, aged 18 years or older, with a performance status (PS) of 0 or 1 Classification by malignancy - Malignancy Genomic information - NO

Objective: Narrative objectives1 - To evaluate the tolerability, safety, and preliminary efficacy of a home-based exercise program in patients discharged after local therapy for liver cancer in a prospective study. Basic objectives2 - Safety,Efficacy

Intervention: Interventions/Control_1 - A 12-week home-based exercise program will be provided to patients aged 18 years or older who have been discharged after local therapy for liver cancer. The program includes resistance training using a theraband targeting three lower limb muscle groups (iliopsoas, quadriceps, gluteus medius) at least 3 days per week, and aerobic exercise in the form of walking. The step count target will start at 3,000 steps per day and increase by 1,000 steps every month. A pedometer and smartphone application will be used to monitor and record adherence.

Eligibility: Age-lower limit - 18 years-old = Gender - Male and Female Key inclusion criteria - Patients who have undergone local therapy for hepatocellular carcinoma (microwave ablation or transarterial chemoembolization) Written informed consent obtained Aged 18 to 80 years Performance status of 0 or 1 Preserved organ function Able to attend outpatient visits Key exclusion criteria - Serious systemic infections or fever >= 38 degrees Celsius Pregnant, possibly pregnant, or breastfeeding women Psychiatric illness or symptoms interfering with participation Ongoing systemic steroid therapy Uncontrolled diabetes (HbA1c >= 8%) or hypertension Unstable angina or myocardial infarction within 6 months Interstitial pneumonia, pulmonary fibrosis, severe emphysema, or acute heart failure History of cerebrovascular disease within 6 months Any condition deemed inappropriate by the attending physician Target Size - 30

Recruitment Status: Recruitment status - Preinitiation Date of protocol fixation - 2025 Year 08 Month 01 Day Date of IRB - 2025 Year 08 Month 01 Day Anticipated trial start date - 2025 Year 09 Month 01 Day Last follow-up date - 2027 Year 03 Month 31 Day

To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000067156

Disclaimer: Curated by HT Syndication.